Life Sciences & Healthcare

COVID-19 has accelerated the pace of change within this sector and exacerbated the global shortage of people with the skills and experience it needs. Looking ahead, there’s no sign of a slowdown or a let-up. In this extraordinary time of change and disruption, you need agile decision-makers who can overcome the challenges and capitalise on the opportunities. With our deep understanding of the global life sciences & healthcare landscape, we can help you find them.

JSS Executive’s healthcare practice works with investors, entrepreneurs through to boards of large cap privately owned & public >1bn ARR organisations, sourcing talent for buy and build innovative start-ups to CEO succession and transition mandates.

  • HCIT & Services
  • Digital Health
  • Value Based Care
  • Payor and Provider
  • Consumer Health

The JSS Life Sciences team understand every stage of the discovery and development cycle, applying our experience to sourcing leaders for a range of vital functions and therapeutic areas. We’ve not only placed specialists from within the sector; we’ve also found talent from outside it – people who can inject fresh ideas and invigorate traditional approaches.

  • BioTechnology
  • Pharma Services/Pharma-IT
  • Diagnostics
  • Medical Devices
  • Digital Therapeutics

Life Sciences & Healthcare

In numbers

  • There are 93 HealthTech Unicorns around the world who are now collectively valued at

    In 2021, there were 51 healthcare unicorns globally

  • In 2021, total disclosed healthcare deal value more than doubled to

    from $66 billion (in 2018: $64 billion)

  • Largest PE deal in Life Sciences & Healthcare headlined by the

    Medline deal and the $17 billion acquisition of Athenahealth